Ainos Issues 2023 Shareholder Letter

Author's Avatar
Jan 17, 2023

SAN DIEGO, CA / ACCESSWIRE / January 17, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, is pleased to provide the following shareholder letter from Ainos' Chairman of the Board, President, and Chief Executive Officer, Mr. Chun-Hsien Tsai.